These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 3470179)

  • 1. New anthracycline analogs in advanced breast cancer.
    Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
    Wadler S; Fuks JZ; Wiernik PH
    J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
    Bastholt L; Dalmark M
    Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
    Hurteloup P; Ganzina F
    Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
    Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
    Brambilla C; Rossi A; Bonfante V; Ferrari L; Villani F; Crippa F; Bonadonna G
    Cancer Treat Rep; 1986 Feb; 70(2):261-6. PubMed ID: 3456271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different cytotoxicity and metabolism of doxorubicin, daunorubicin, epirubicin, esorubicin and idarubicin in cultured human and rat hepatocytes.
    Le Bot MA; Bégué JM; Kernaleguen D; Robert J; Ratanasavanh D; Airiau J; Riché C; Guillouzo A
    Biochem Pharmacol; 1988 Oct; 37(20):3877-87. PubMed ID: 3190734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline analogs: the past, present, and future.
    Weiss RB; Sarosy G; Clagett-Carr K; Russo M; Leyland-Jones B
    Cancer Chemother Pharmacol; 1986; 18(3):185-97. PubMed ID: 2948729
    [No Abstract]   [Full Text] [Related]  

  • 11. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
    Jain KK; Casper ES; Geller NL; Hakes TB; Kaufman RJ; Currie V; Schwartz W; Cassidy C; Petroni GR; Young CW
    J Clin Oncol; 1985 Jun; 3(6):818-26. PubMed ID: 3859587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adriamycin and its analogs].
    Arcamone F
    Tumori; 1984 Apr; 70(2):113-9. PubMed ID: 6587651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II trial of idarubicin in patients with advanced lymphoma.
    Gillies H; Liang R; Rogers H; Harper P; Parapia L; Cox G; Johnson S
    Cancer Chemother Pharmacol; 1988; 21(3):261-4. PubMed ID: 3162850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
    Chisesi T; Capnist G; de Dominicis E; Dini E
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
    Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
    Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
    [No Abstract]   [Full Text] [Related]  

  • 17. Phase II trial with oral idarubicin in advanced breast cancer.
    Lopez M; Di Lauro L; Papaldo P; Lazzaro B; Ganzina F; Di Pietro N
    Invest New Drugs; 1986; 4(1):39-42. PubMed ID: 3457780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of oral idarubicin (4-demethoxydaunorubicin) in advanced breast cancer.
    Stuart NS; Cullen MH; Priestman TJ; Blackledge GR; Tyrrell CJ
    Cancer Chemother Pharmacol; 1988; 21(4):351-4. PubMed ID: 3163529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
    Smith DB; Howell A
    Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.